Company: ENTXW
Filing Date: 2025-01-10
Form Type: 424B5
Source: 0001178913-25-000079
Chunk: 1

Company: Entera Bio Ltd.
Filing Date: 2025-01-10
Form: 424B5
Chunk 1
---
 our sales agent or principal using commercially reasonable efforts consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. Our ordinary shares trade on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “ENTX”. On January 9, 2025, the closing price for our ordinary shares on Nasdaq was $2.45 per share. Investing in our ordinary shares involves risks. See “Risk Factors” beginning on page S-3 of this prospectus supplement, the accompanying prospectus and in the reports we file with the Securities and Exchange Commission (the “SEC”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), incorporated by reference in this prospectus supplement before making a decision to invest in our ordinary shares. Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. Leerink Partners The date of this Supplement is January 10, 2025 ABOUT THIS PROSPECTUS SUPPLEMENT This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of the offering. The second part is the accompanying prospectus, which is part of a registration statement that we filed with the SEC, using a “shelf” registration process. The accompanying prospectus describes more general information, some of which may not apply to this offering. As of the date of this Supplement, out of 5,000,000 shares originally registered, we had sold 4,940,156 ordinary shares through Leerink Partners under the prospectus supplement and the accompanying prospectus for an aggregate gross sales price of approximately $10.1 million. Under this prospectus supplement, we may from time to time offer and sell up to an additional 30,000,000 ordinary shares at prices and on terms to be determined by market conditions at the time of the offering. The 30,000,000 ordinary shares that may be sold under this prospectus supplement are included in the $100.0 million of securities that may be sold under our shelf registration statement, which became effective on June 9, 2022. However, in no event will we offer securities pursuant to this prospectus supplement to the extent the aggregate offering price of such securities exceeds the remaining aggregate offering amount registered under the registration statement of which this prospectus supplement